Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia

IDrugs

Volumn 13, Issue 11, 2010, Pages 782-792

  Ghali, Jalal K ^a   Zmily, Hammam D ^b   Farah, Jareer O ^b   Daifallah, Suleiman ^b  

^a DETROIT MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CARBAMAZEPINE; CL 385004; CONIVAPTAN; DEMECLOCYCLINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LACTULOSE; LITHIUM; LIXIVAPTAN; MOXIFLOXACIN; MOZAVAPTAN; OXCARBAZEPINE; PEPTIDE HORMONE ANTAGONIST; PLACEBO; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN; WAY 140288;

ABDOMINAL PAIN; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASPIRATION PNEUMONIA; BACTERIAL PERITONITIS; BRADYCARDIA; BRAIN DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DIZZINESS; DOG; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; FLATULENCE; FREE WATER CLEARANCE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPONATREMIA; IN VITRO STUDY; LIVER CIRRHOSIS; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MYOSITIS; NEPHROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM URINE LEVEL; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL HERNIA; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; URINE OSMOLALITY; URINE VOLUME; VASOPRESSIN BLOOD LEVEL; VITAL SIGN; XEROSTOMIA;

ADMINISTRATION, ORAL; ANIMALS; ARGININE VASOPRESSIN; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DOGS; HEART FAILURE; HUMANS; HYPONATREMIA; PYRROLES; RATS; RECEPTORS, VASOPRESSIN;

EID: 78650268272     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. 291879 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin- 10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): An orally active arginine vasopressin antagonist with selectivity for V2 receptors. Albright JD, Reich MF, Santos EGD, Dusza JP, Sum FW, Venkatesan AM, Coupet J, Chan PS, Ru X, Mazandarani H, Bailey T J MED CHEM 1998 41 14 2442-2444 Two different methods for the synthesis of lixivaptan, both involving acylation of the benzodiazepene nitrogen of the tricyclic compound 10,11-dihydro-5H-pyrrolo[2,1-c][1,4] benzodiazepine, as well as the results of initial in vitro and in vivo studies, are presented.
2. 294730 Arginine vasopressin (AVP) antagonists. Pyrrolo [2,1-c] [1,4] benzodiazepines. Albright JD, Reich MF, Santos ED, Dusza JP, Sum FW, Venkatesan AM, Coupet J, Chan PS, Mazandarani RH, Bailey T ACS 1998 216 Boston MEDI 018
3. 329378 Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene. Mayinger B, Hensen J EXP CLIN ENDOCRINOL DIABETES 1999 107 3 157-165
4. 330289 4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1] benzazepine derivatives as orally active arginine vasopressin receptor antagonists. Aranapakam V, Albright JD, Grosu GT, Chan PS, Coupet J, Saunders T, Ru X, Mazandarani H BIOORG MED CHEM LETT 1999 9 13 1733-1736
5. 330298 5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine- 10(11H)-yl carbonyl)-2-pyridinyl] benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists. Aranapakam V, Albright JD, Grosu GT, Delos Santos EG, Chan PS, Coupet J, Ru X, Saunders T, Mazandarani H BIOORG MED CHEM LETT 1999 9 13 1737-1740
6. 363848 Pharmacodynamic (PD) effects of a novel, non-peptide, V2 receptor antagonist, VPA-985 (VPA), given with hydrochlorothiazide (H). Patat A, Ellis Grosse EJ, Orczyk G, Gandon JM CLIN PHARMACOL THER 2000 67 2 Abs PI-84
7. 366193 The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery. Ashwell MA, Bagli JF, Caggiano TJ, Chan PS, Molinari AJ, Palka C, Park CH, Rogers JF, Sherman M, Trybulski EJ, Williams DK BIOORG MED CHEM LETT 2000 10 8 783-786
8. 367115 The efffects of VPA-985 a vasopressin receptor antagonist on water metabolism in patients with hyponatremia: A multi-center randomized placebo controlled trial. Wong F, Blei AT, Blendis M, Robertson GL, Thuluvath PT GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 1094
9. 371451 The synthesis and vaspopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo- [3,4-d]thieno[3,2-b] azepines. Albright JD, Delos santos EG, Dusza JP, Chan PS, Coupet J, Ru X, Mazandarani H BIOORG MED CHEM LETT 2000 10 8 695-698
10. 381993 Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW J AM SOC NEPHROL 1999 10 10 2165-2170
11. 382000 VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: A doubleblind placebo controlled multicenter trial. Gerbes AL, Guelberg V, Decaux G, Gross P, Massien C, Djian J HEPATOLOGY 1999 30 No 4 Pt 2 419A
12. 382006 Interaction between VPA-985, an ADH (V2) antagonist, and furosemide. Swan SK, Lambrecht LJ, Orczyk GP, Ellis Grosse EJ J AM SOC NEPHROL 1999 10 124A
13. 382007 Pharmacodynamic effects of VPA-985, an ADH (V2) antagonist, in normal volunteers. Swan SK, Anjum S, Lambrecht LJ, Orczyk GP, Ellis Grosse EJ J AM SOC NEPHROL 1999 10 124A
14. 382008 Treatment of hyponatremia (HYPO) with VPA-985. Gross P, Decaux G, Gerbes A, Djian J J AM SOC NEPHROL 1999 10 121A
15. 382010 Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, VPA-985. Decaux G, Hannotier P, Pennickx R, Soupart A, Djian J J AM SOC NEPHROL 1999 10 120A
16. 382011 Correction of hyponatremia by a single oral dose of 75 mg of the non-peptide vasopressin V2 antagonist VPA-985 in hyponatremic patients receiving carbamazepine (CBZ) (Tegretol) or oxcarbazepine (OBZ) (Trileptal). Bichet DG, Remillard G, Madore F, Mallie JP, Lonergan M, Deslauriers N, Drouin M, Leduc B, Ellis Grosse EJ, Orczyk GP J AM SOC NEPHROL 1999 10 119A
17. 382013 VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, Tanikella T et al ADV EXP MED BIOL 1998 449 439-443
18. 382015 VPA-985: A novel non-peptide competitive vasopressin receptor antagonist for the treatment of dilutional hyponatremia. Epstein M, Orczyk G, Muralidharan G, Fruncillo R J AM SOC NEPHROL 1998 9 Abs A0544
19. 382016 In vitro pharmacology of VPA-985, a non-peptide V2 selective vasopressin antagonist. Park CH, Lock YW, Tanikella TK, Ning X, Dusza JP, Albright JP, Spinelli W J AM SOC NEPHROL 1998 9 Abs A0120
20. 382017 Pharmacological characterization of VPA-985, a potent nonpeptidic orally-active and selective vasopressin (AVP) V2 receptor antagonist. Chan PS, Lai F, Ru X, Sherpherd C, Bailey T, Li PJ, Dusza JP, Albright JD, Cervoni P, Spinelli W J AM SOC NEPHROL 1998 9 Abs A0081
21. 382018 Effects of an oral, nonpeptide, selective V-2 receptor vasopressin antagonist in patients with chronic heart failure. Abraham WT, Oren RM, Crisman TS, Robertson AD, Shakar S, Lowes BD, Panther L, Kelley P, Pies CJ, Bristow MR, Schrier RW J AM COLL CARDIOL 1997 29 2 Suppl A Abs 727-1
22. 382019 Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects. Muralidharan G, Meng X, DeCleene SA, Cevallos WH, Fruncillo R, Hicks D, Orczyk GP CLIN PHARMACOL THER 1999 65 2 189
23. 421488 Drug development: Lixivaptan. American Home Products Corp Company Communication 2001 September 06
24. 515544 Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists. Sum FW, Dusza J, Santos ED, Grosu G, Reich M, Du X, Albright JD, Chan P, Coupet J, Ru X, Mazandarani H et al BIOORG MED CHEM LETT 2003 13 13 2195-2198
25. 532143 Cardiokine, Inc. completes $37 million private equity financing. Cardiokine, Inc. PRESS RELEASE 2004 April 13
26. 558528 Tolvaptan (Otsuka). Doggrell SA CURR OPIN INVESTIG DRUGS 2004 5 9 977-983
27. 664151 Astellas launches Vaprisol for the treatment of euvolemic hyponatremia in hospitalized patients. Astellas Pharma US Inc Press Release 2006 April 26
28. 730873 Otsuka to launch oral vasopressin V2-receptor antagonist. Otsuka Pharmaceutical Co Ltd Press Release 2006 October 11
29. 810229 Biogen Idec and Cardiokine partner to develop lixivaptan, a novel vasopressin antagonist. Biogen Idec Inc PRESS RELEASE 2007 July 02
30. 851054 Identification and synthesis of major metabolites of vasopressin V2-receptor agonist WAY-151932, and antagonist, lixivaptan. Molinari AJ, Trybulski EJ, Bagli J, Croce S, Considine J, Qi J, All K, DeMaio W, Lihotz L, Cochran D BIOORG MED CHEM LETT 2007 17 21 5796-5800
31. 869527 NCT00578695: The BALANCE Study: Treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation. Cardiokine Inc clinicaltrials.gov 2007
32. 940574 Effects of lixivaptan, a novel vasopressin V2 receptor antagonist, in chronic heart failure: Results front a double-blind, placebo-controlled, multiple-dose study. Abraham W, Goldsmith S, Gottlieb S J CARD FAIL 2008 14 6 Suppl 1 Abs 225
33. 1038467 Otsuka applies for SAMSCA for cardiac edema in Japan. Pharma Jpn 2009 2152 August 24 12
34. 1079336 Biogen Idec Inc: Form 10-K for the year ended 31 December 2009. Biogen Idec Inc Form 10-K 2010 February 09
35. 1086938 Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP HEPATOLOGY 2002 36 5 1197-1205
36. 1086939 Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gerbes AL, Golberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J GASTROENTEROLOGY 2003 124 4 933-939
37. 1086940 A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Wong F, Blei AT, Blendis LM, Thuluvath PJ HEPATOLOGY 2003 37 1 182-191
38. 1086941 (4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators. Venkatesan AM, Grosu GT, Failli AA, Chan PS, Coupet J, Saunders T, Mazandarani H, Ru X BIOORG MED CHEM LETT 2005 15 22 5003-5006
39. 1086942 Aquaretic efect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW J AM COLL CARDIOL 2006 47 8 1615-1621
40. 1104333 NCT01055912: Study to evaluate the effects of oral administration of lixivaptan in patients with congestive heart failure. CardioKine Inc clinicaltrials.gov 2010
41. 1116087 Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V-2 receptor antagonist VPA-985. Decaux G J LAB CLIN MED 2001 138 1 18-21
42. 1116117 Effects of single dose administration of lixivaptan, a selective V2 receptor antagonist, or furosemide in healthy volunteers. Abraham W, Ghali J, Braman V, Nirula A EUR J HEART FAIL 2010 9 1 Abs 1064
43. 1116118 Effect of chronic administration of the vasopressin V2 receptor antagonist lixivaptan (VPA-985) on renal and cardiovascular functions in a rat model of heart failure. Radin J, McCune S, Park S, Orlandi C, Ticho B EUR J HEART FAIL 2009 8 2 Abs 620
44. 1116121 The effect on renal function of lixivaptan (VPA-985), a vasapressin V2 receptor antagonist, in combination with furosernide. Orlandi C, Ticho B EUR J HEART FAIL 2009 8 2 Abs 618
45. 1125524 Heart failure-related hospitalization in the US, 1979 to 2004. Fang J, Mensah GA, Croft JB, Keenan NL J AM COLL CARDIOL 2008 52 6 428-434
46. 1125525 The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. Ghali JK, Tam SW J CARD FAIL 2010 16 5 419-431
47. 1125526 Mechanisms, risks, and new treatment options for hyponatremia. Ghali JK CARDIOLOGY 2008 111 3 147-157
48. 1125527 Diuretic complications. Greenberg A AM J MED SCI 2000 319 1 10-24
49. 1125528 Association between diuretic use, clinical response, and death in acute heart failure. Philbin EF, Cotto M, Rocco TA, Jenkins PL AM J CARDIOL 1997 80 4 519-522
50. 1125535 Conivaptan and its role in the treatment of hyponatremia. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD DRUG DES DEVEL THER 2009 3 253-268
51. 1125553 Therapeutic potential of vasopressin receptor antagonists. Ali F, Guglin M, Vaitkevicius P, Ghali JK DRUGS 2007 67 6 847-858
52. 1136190 Congestive heart failure (CHF), water retention, and arginine vasopressin: Response to V2 vasopressin receptor antagonist. Shamshirsaz AA, Abraham WT, McFann K, Oren RM, Schrier RW J AM SOC NEPHROL 2004 10 15 Abs F-PO285
53. 1136200 Single dose pharmacokinetic (PK) -pharmacodynamic (PD) profile of VPA-985, a novel, V2 receptor antagonist, in patients with congestive heart failure (CHF). Ellis-Grosse EJ, Meng X, Orczyk GP AAPS PHARMSCI 1999 1 S1 Abs
54. 1136203 Dynamic effects of a novel, non-peptide ADH(V2) antagonist in cirrhotic patients with ascites. Guyader D Hepatology 1998 28 4 Part 2 Abs 1587
55. 1137532 Studies on substances with antitumor activity. XXXVI. Anthramycin and similar compounds. I. Synthesis of 10,11-diidro-5H-pyrrole-(2,1-c)(1,4)- benzodiazepine. Artico M, De Martino G, Filacchioni G, Giuliano R FARMACO [SCI] 1969 24 3 276-284
56. 1137534 Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4] benzodiazepine as central nervous system agents. Wright WB, Greenblatt EN, Day IP, Quinones NQ, Hardy RA J MED CHEM 1980 23 4 462-465
57. 1140107 Osmotic and nonosmotic control of vasopressin release. Schrier RW, Berl T, Anderson RJ AM J PHYSIOL - RENAL PHYSIOL 1979 236 4 F321-F332
58. 1140111 Molecular physiology of urinary concentrating mechanism: Regulation of aquaporin water channels by vasopressin. Knepper MA AM J PHYSIOL - RENAL PHYSIOL 1997 272 1 Pt 2 3F-12F
59. 1140112 Renal aquaporin water channels: From molecules to human disease Schrier RW, Cadnapaphornchai MA PROG BIOPHYS MOL BIOL 2003 81 2 117-131
60. 1140144 Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA J AM COLL CARDIOL 2007 49 22 2151-2159
61. 1140149 Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, Ghali JK, Selaru P, Chanoine F, Pressler ML, Konstam MA Circulation 2001 104 20 2417-2423